Eszopiclone + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Obstructive Sleep Apnea Syndrome

Conditions

Obstructive Sleep Apnea Syndrome

Trial Timeline

Aug 1, 2003 → Jan 1, 2004

NCT ID

NCT00685269

About Eszopiclone + Placebo

Eszopiclone + Placebo is a phase 2 stage product being developed by Sumitomo Pharma for Obstructive Sleep Apnea Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00685269. Target conditions include Obstructive Sleep Apnea Syndrome.

What happened to similar drugs?

20 of 20 similar drugs in Obstructive Sleep Apnea Syndrome were approved

Approved (20) Terminated (2) Active (0)

✅lysozyme 90 mg + PlaceboEisaiApproved

✅Eszopiclone + Placebo controlSumitomo PharmaApproved

✅Arformoterol tartrate + Placebo: Normal SalineSumitomo PharmaApproved

✅Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved

✅Lunesta + Placebo controlSumitomo PharmaApproved

✅Nebulized arformoterol + SalmeterolSumitomo PharmaApproved

✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01102270	Phase 1	Completed	Jan 1, 2009	May 1, 2010	Obstructive Sleep Apnea
NCT00645944	Pre-clinical	Completed	Apr 1, 2008	Apr 1, 2011	Insomnia
NCT00826111	Approved	Completed	Aug 1, 2007	Jul 1, 2011	Depression
NCT00414037	Approved	Terminated	Dec 1, 2006	Dec 1, 2008	Primary Insomnia
NCT00386334	Approved	Completed	Oct 1, 2006	Feb 1, 2008	Insomnia
NCT00833547	Pre-clinical	Completed	Sep 1, 2006	Sep 1, 2012	Schizophrenia
NCT00392041	Approved	Completed	Aug 1, 2006	Mar 1, 2009	Fibromyalgia
NCT00365976	Approved	Completed	Aug 1, 2006	Sep 1, 2010	Primary Insomnia
NCT00555750	Pre-clinical	Completed	Mar 1, 2006	Aug 1, 2008	Primary Insomnia
NCT00374192	Pre-clinical	Completed	Feb 1, 2006	Jul 1, 2007	Menopause
NCT00368056	Phase 3	Completed	Apr 1, 2005	Jun 1, 2006	Primary Insomnia
NCT00368160	Phase 1	Completed	Mar 1, 2004	Jul 1, 2005	Insomnia
NCT00367965	Phase 3	Completed	Feb 1, 2004	Nov 1, 2004	Insomnia
NCT00366093	Phase 3	Completed	Feb 1, 2004	Jan 1, 2005	Insomnia
NCT00352144	Phase 3	Completed	Oct 1, 2003	Oct 1, 2004	Primary Insomnia
NCT00685269	Phase 2	Completed	Aug 1, 2003	Jan 1, 2004	Obstructive Sleep Apnea Syndrome

Competing Products

20 competing products in Obstructive Sleep Apnea Syndrome

See all competitors

Product	Company	Stage	Hype Score
Daridorexant + Placebo	Idorsia	Phase 1	23
Mavacamten + Placebo	LianBio	Phase 3	30
CT-G20 + Placebo	Celltrion	Phase 1	21
Reldesemtiv + Placebo	Astellas Pharma	Phase 2	35
Placebo + Lemborexant 10 mg + Lemborexant 25 mg + Placebo + Lemborexant 10 mg	Eisai	Phase 1	29
lysozyme 90 mg + Placebo	Eisai	Approved	43
Placebo + Lemborexant 10 mg + Placebo + Lemborexant 10 mg	Eisai	Phase 1	29
Eloralintide + Placebo	Eli Lilly	Phase 3	47
Tirzepatide + Placebo	Eli Lilly	Phase 3	40
Arformoterol tartrate inhalation solution + Arformoterol 25 ųg BID + Formoterol 12 ųg BID + Placebo	Sumitomo Pharma	Phase 3	40
arformoterol tartrate inhalation solution + arformoterol tartrate inhalation solution + arformoterol tartrate inhalation solution + Salmeterol + Placebo	Sumitomo Pharma	Phase 3	40
arformoterol + salmeterol	Sumitomo Pharma	Pre-clinical	26
Arformoterol + Placebo	Sumitomo Pharma	Phase 3	40
Eszopiclone + Placebo control	Sumitomo Pharma	Approved	43
Eszopiclone + Placebo	Sumitomo Pharma	Phase 1	29
Arformoterol tartrate + Placebo: Normal Saline	Sumitomo Pharma	Approved	43
Arformoterol tartrate inhalation solution + Tiotropium	Sumitomo Pharma	Approved	35
Lunesta + Placebo control	Sumitomo Pharma	Approved	43
Nebulized arformoterol + Salmeterol	Sumitomo Pharma	Approved	39
Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + Placebo	Sumitomo Pharma	Approved	43